PRFX Stock Analysis: Buy, Sell, or Hold?
PRFX - PainReform Ltd. Ordinary Shares
$1.24
-0.11 (-8.15%)
▼
5d:
-10.79%
30d:
-20.0%
90d:
-53.21%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jun 25, 2026
0d
Get Alerted When PRFX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called PRFX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PRFX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PRFX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PRFX is currently trading at $1.24, which is considered oversold relative to its 30-day fair value range of $1.26 to $1.76.
Technical Outlook: Technically, PRFX is showing sideways momentum. The price is currently testing key support at $1.30. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: PRFX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.00 (+867.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PRFX is showing sideways momentum. The price is currently testing key support at $1.30. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: PRFX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.00 (+867.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.26 -
$1.76
Company Quality Score
47/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-8.1%)
- BULLISH: Trading 867.7% below Wall St target ($12.00)
- CAUTION: 5-day price weakness (-10.8%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.26 -
$1.76
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.30
Resistance Level
$5.39
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Wall Street Target
$12.00
(+867.7%)
Share & Embed Analysis
Last updated: July 14, 2026 12:41 AM ET
Data refreshes hourly during market hours. Next update: 1:41 AM
Data refreshes hourly during market hours. Next update: 1:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRFX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
